Darunavir: A Review of Its Use in the Management of HIV-1 Infection

@article{Deeks2013DarunavirAR,
  title={Darunavir: A Review of Its Use in the Management of HIV-1 Infection},
  author={Emma D. Deeks},
  journal={Drugs},
  year={2013},
  volume={74},
  pages={99-125}
}
The latest HIV-1 protease inhibitor (PI) darunavir (Prezista™) has a high genetic barrier to resistance development and is active against wild-type HIV and HIV strains no longer susceptible to some older PIs. Ritonavir-boosted darunavir, as a component of antiretroviral therapy (ART), is indicated for the treatment of HIV-1 infection in adult and paediatric patients (aged ≥3 years), with or without treatment experience (details vary depending on region of approval). Several open-label or… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS